Solid-phase peptide synthesis (SPPS): the chemistry behind every catalog peptide

Solid-phase peptide synthesis (SPPS) is the production method behind essentially every synthetic peptide in our catalog and across the broader pharmaceutical-grade peptide market. Understanding the chemistry helps buyers interpret what their analytical packet actually means and what distinguishes a well-run synthesis from a sloppy one.

This article covers the SPPS principles a procurement-team or research-lab reader should understand to read a peptide COA with informed skepticism.

The Merrifield insight

SPPS was developed by Bruce Merrifield in 1963 at Rockefeller University and won the Nobel Prize in Chemistry in 1984. The core insight: instead of synthesizing peptides in solution where each intermediate must be isolated and purified before the next reaction, anchor the growing peptide to an insoluble polymer resin. After each coupling step, the resin is simply washed, soluble byproducts wash away while the resin-bound peptide stays put. This transforms peptide synthesis from a slow series of isolated reactions into a repeated cycle of coupling and washing.

The practical consequence: SPPS scales gracefully from milligram research batches to kilogram commercial production using the same chemistry. Solution-phase synthesis doesn't scale this way, which is why solid-phase has been the dominant production method for the last 40 years.

The Fmoc strategy

Modern SPPS uses the Fmoc (fluorenylmethyloxycarbonyl) protecting-group strategy almost exclusively for pharmaceutical-grade peptide manufacturing. Fmoc protects the α-amino group of each incoming amino acid; side-chain functional groups carry orthogonal protecting groups (typically tBu, Trt, Boc, OtBu, Pbf) that survive the Fmoc-removal conditions but are removed at the final TFA cleavage step.

The Fmoc-cycle iteration:

1. **Deprotection**, Treat the resin with 20% piperidine in DMF. The piperidine cleaves the Fmoc group via β-elimination, exposing the α-amine for the next coupling.
2. **Coupling**, Activate the next Fmoc-protected amino acid (typically with HBTU/HATU/DIC + HOBt as activators) and add to the deprotected resin. The activated carbonyl reacts with the exposed amine to form the new peptide bond.
3. **Wash**, Rinse away excess reagents and soluble byproducts with DMF.
4. **Repeat**, Loop back to deprotection for the next residue.

A 30-residue peptide requires 30 iterations of this cycle, with 29 amino-acid couplings total. After the final residue, the peptide is cleaved from the resin with TFA cocktail (typically 95% TFA + scavengers like water, triisopropylsilane, ethanedithiol, the scavenger choice depends on which side-chain protecting groups are present).

Cycle yield is the real number, not total yield

Total isolated yield of a synthesized peptide depends on cycle yield raised to the number of residues. If each coupling cycle proceeds at 99% efficiency (which is excellent), a 30-residue peptide produces:

> 0.99^29 = 0.747

About 75% theoretical yield. At 98% cycle efficiency (still good), the same peptide produces 56% theoretical yield. At 95% cycle efficiency (which still passes many QC gates), the same peptide produces only 23% theoretical yield.

The mathematics is unforgiving. The longer the peptide, the more cycle yield matters. A 39-residue peptide like Tirzepatide at 99% cycle efficiency gives 68% theoretical; at 95% cycle efficiency it gives 14%. This is why Tirzepatide synthesis is a craft, not a recipe, small cycle-efficiency improvements produce large product-yield improvements at scale.

Where side reactions come from

Several systematic side reactions degrade SPPS yield at the cycle-step level. Understanding them helps interpret what the analytical packet shows:

Deletion sequences, When a coupling cycle fails partially, some resin-bound peptide chains skip the residue and proceed to the next coupling with the chain one residue short. The result is a deletion-sequence impurity that differs from the target peptide by exactly one amino-acid mass at a specific position. Deletion-sequence impurities elute very close to the target peptide on RP-HPLC, which is why HPLC purity at ≥99% doesn't guarantee identity, the deletion-sequence variant can hide under the main peak.

Truncation sequences, When the coupling fails completely and the failed chain doesn't get capped, subsequent coupling cycles may add residues to the truncated chain, producing a shifted-sequence impurity. Truncations are less common in modern SPPS because most production protocols include an acetic-anhydride capping step after each coupling to terminate failed chains.

Aspartimide formation, Asp-X sequences (especially Asp-Gly) are prone to aspartimide formation during repeated piperidine exposure across multiple cycles. The aspartimide intermediate can re-open to either the original Asp-X peptide or a β-Asp isomer. The β-Asp impurity is challenging to separate chromatographically and is one of the harder side reactions to control on long peptides with multiple Asp residues.

Racemization, Some amino acids (especially His and Cys) are prone to α-carbon racemization during coupling activation, producing D-enantiomer impurities at the racemized position. The D-enantiomer impurity is biologically distinct from the L-enantiomer target but is invisible to standard mass spec (same mass), chiral HPLC or amino-acid-analysis after total hydrolysis is the relevant analytical test.

Oxidation, Met and Cys residues oxidize during long synthesis cycles, especially under repeated piperidine exposure. The +16 Da oxidation product is mass-spec-visible and chromatographically distinct from the parent peptide.

What the analytical packet should show

For a well-run SPPS synthesis, the released-batch analytical packet should report:

• HPLC purity, target ≥99.0% by area at the analytical reinjection. The chromatogram should show one dominant peak with closely-eluting impurities below 0.5% individually.
• ESI mass spec, observed mass within 0.5 Da of theoretical for the monoisotopic or average mass (depending on what the COA reports).
• LC-MS/MS sequence verification, for peptides above 15 residues, the tandem-MS b- and y-ion ladder should cover the full sequence and match the labeled sequence at the residue level.
• Counter-ion content, typically 4-12% by mass for acetate-salt peptides, 5-15% for TFA-salt. The counter-ion is identified explicitly on the COA.
• Water content, Karl Fischer titration, typically ≤8% for lyophilized vials.
• Residual solvent screening, gas chromatography against pharmacopeia limits for any solvents used in the purification step.

For more on what each COA field actually measures and how to spot a doctored document, see our COA buyer's field guide.

How synthesis quality varies between manufacturers

Two manufacturers running the same SPPS protocol can produce meaningfully different product quality because of differences in:

1. **Cycle yield discipline**, How rigorously they monitor coupling completion at each step. The good manufacturers use Kaiser test or chloranil test on the resin after each coupling to confirm completion before advancing; the sloppy ones run on assumption.
2. **Purification cutoff stringency**, How tightly they cut against deletion-sequence and aspartimide-isomer impurities during preparative HPLC. Tight cutoffs reduce yield but raise purity; loose cutoffs do the opposite.
3. **Counter-ion exchange completeness**, How thoroughly they exchange TFA-salt material to the target counter-ion. Incomplete exchange leaves residual TFA on acetate-labeled material.
4. **Analytical depth at release**, Whether the released batch carries actual sequence verification by LC-MS/MS or only mass-alone identity confirmation.

The 10× price variance across the China peptide supply chain reflects these differences, not just margin differences. See our supplier qualification guide for how to vet a supplier against synthesis-quality signals.